Logo

BeiGene Receives EMA’s CHMP Positive Opinion Recommending Approval of Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Share this
BeiGene

BeiGene Receives EMA’s CHMP Positive Opinion Recommending Approval of Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Shots:

  • The EMA’s CHMP has issued a positive opinion recommending approval of tislelizumab as monotx. for adult patients with unresectable, LA or metastatic ESCC after prior Pt-based CT
  • The MAA was based on the P-III study (RATIONALE 302) evaluating tislelizumab (humanized IgG4 anti-PD-1 mAb) vs CT in 513 patients from 132 research sites in 11 countries in Asia, EU & North America. The study met its 1EPs & showed benefit, m-OS was 8.6 vs 6.3mos. & the safety profile was consistent with prior trials
  • The MAA also incl. safety data for 1972 patients who received tislelizumab monotx. in 7 clinical trials. Additionally, regulatory submissions for tislelizumab are under review by authorities in the US, UK, Australia, China, New Zealand, Brazil, Korea, Switzerland & Indonesia

Ref: BeiGene   | Image: BeiGene

Related News:- Galapagos to Acquire CellPoint and AboundBio to Advance Cell Therapies for the Treatment of Advanced Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions